Comparative Pharmacology
Head-to-head clinical analysis: HYDRODIURIL versus SALURON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRODIURIL versus SALURON.
HYDRODIURIL vs SALURON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-chloride symporter in the distal convoluted tubule of the kidney, increasing excretion of sodium and water, reducing plasma volume and cardiac output.
Saluron (hydroflumethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, increasing excretion of sodium, chloride, and water. It also reduces peripheral vascular resistance through direct vasodilatory effects.
25-100 mg orally once daily. For hypertension: 12.5-25 mg once daily.
Initial: 50-100 mg orally once daily; maintenance: 50-200 mg orally once daily or in divided doses.
None Documented
None Documented
Terminal elimination half-life is approximately 5.6–14.8 hours (mean ~10 hours); clinically, duration of diuresis correlates with half-life, allowing once or twice daily dosing.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged in renal impairment (up to 24-36 hours with creatinine clearance <30 mL/min).
Renal: approximately 95% eliminated unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Primarily renal (≥95%) via glomerular filtration and tubular secretion; approximately 70% as unchanged drug, 25% as metabolites. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic